Navigation Links
Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR

oster on Sunday, April 15, 2007, titled, "Tanespimycin (17-AAG, KOS-953): No Effects on QTc Interval Using Two Formulations" (abstract #1544). A second poster, entitled "Preclinical Safety Profile of Tanespimycin (KOS-953) -- a Heat Shock Protein 90 (Hsp90) Inhibitor" (abstract #1568) reported on preclinical toxicology studies with tanespimycin and confirmed that in these studies tanespimycin had no adverse effect on QTc interval.

Results of Cardiac Monitoring Analyses

To evaluate whether tanespimycin had any effect on the QTc interval, patients in clinical trials of tanespimycin underwent ECG monitoring prior to the study, before dosing, near the expected time of maximal plasma concentrations within 20 minutes after the infusion, as well as at the end of the study. ECG intervals were measured by a dedicated cardiologist at Memorial Sloan-Kettering Cancer Center (MSKCC) or by a central cardiologist at an independent third-party laboratory.

In trials conducted by MSKCC, under the auspices of CTEP, tanespimycin was administered in an egg-phospholipid/4% DMSO formulation. In trials of tanespimycin sponsored by Kosan, tanespimycin was administered in a Cremophor-based formulation. There was no evidence in any of these trials that tanespimycin prolonged the QTc interval (a prolongation of the interval can lead to ventricular arrhythmia).

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multipl
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:9/23/2014)... September 23, 2014 Avillion ... the appointment of Jarrod Longcor as ... is responsible for structuring, negotiating and executing successful ... well as providing management and strategic leadership to ... Executive leadership team. Mr Longcor brings ...
(Date:9/22/2014)... , September 23, 2014 , ... health authorities, increasing rigor for trial master file (TMF) ... industry,s largest TMF survey to date reveals an increase ... to provide auditors with remote access to their electronic ... owners surveyed in the Veeva 2014 Paperless ...
(Date:9/22/2014)... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... $200 million of its common stock in an underwritten ... Merrill Lynch are acting as joint book-running managers for ... option to purchase additional shares of its common stock. ... offering are being sold by Avanir.  The offering is ...
Breaking Medicine Technology:Avillion Appoints Jarrod Longcor as Chief Business Officer 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
... March 15 URL Pharma, Inc. today announced the launch of an expanded ... eligible for low-cost Colcrys therapy. Uninsured and Medicare Part D patients with household incomes ... Colcrys PAP. This expanded program is available to patients immediately. , ... ...
... , March 15 Watson Pharmaceuticals, Inc. ... subsidiary, Watson Laboratories, Inc. – Florida , has ... (FDA) for its Abbreviated New Drug Application (ANDA) for ... Laboratories International SRL,s Cardizem® LA product.  Watson intends to ...
Cached Medicine Technology:URL Pharma Expands Colcrys(R) Patient Assistance Program 2URL Pharma Expands Colcrys(R) Patient Assistance Program 3URL Pharma Expands Colcrys(R) Patient Assistance Program 4URL Pharma Expands Colcrys(R) Patient Assistance Program 5URL Pharma Expands Colcrys(R) Patient Assistance Program 6Watson Receives FDA Approval for Generic Cardizem(R) LA 2Watson Receives FDA Approval for Generic Cardizem(R) LA 3
(Date:9/23/2014)... you may want to get screened and treated for ... According to a first-of-its-kind study in the October ... of the American Society of Anesthesiologists (ASA), patients with ... prior to surgery are less likely to develop serious ... "OSA is a common disorder that affects millions and ...
(Date:9/23/2014)... Act "Obamacare" was signed into law in ... healthcare system since the 1960s. Designed to provide medical ... as an unwarranted intrusion into the affairs of private ... of healthcare systems in six Western countries, published last ... a move away from privatized medicine toward state-sponsored healthcare ...
(Date:9/23/2014)... ADOMANI, Inc. has announced that industry ... He is a 13-year veteran in the school, commercial and ... A-Z Bus Sales of Colton, California. While with A-Z Mr. ... top line revenues, profit and market penetration by double digits. ... to all-electric or plug-in hybrid vehicle conversions. They have ...
(Date:9/23/2014)... Carbon nanotubes serve as bridges that allow electrical ... patches invented at Rice University and Texas Children,s ... Jacot and chemical engineer and chemist Matteo Pasquali ... nanotubes. The patches are made of a sponge-like ... body,s extracellular matrix. , The nanotubes overcome a ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 eCaring, ... it has entered into a contract to provide its ... to Elderplan, Inc., one of New York City’s largest ... will deploy the eCaring system to help enhance the ... , “For nearly 30 years, Elderplan has been at ...
Breaking Medicine News(10 mins):Health News:New research suggests sleep apnea screening before surgery 2Health News:Life, liberty, and the pursuit of healthcare? 2Health News:ADOMANI Announces Jim Reynolds to Take Over as President and CEO 2Health News:Nanotubes help healing hearts keep the beat 2Health News:Nanotubes help healing hearts keep the beat 3Health News:eCaring Signs Care Management Contract with Elderplan, Inc. 2
... 2010 -- The American College of Cardiology and ... Interventions has been accepted for coverage by Thomson ... the Journal Citation Reports. The Journal will receive ... "The Editorial Board and the American College of Cardiology ...
... According to a ... programs, such as Medicare and Medicaid, have prompted hospitals to shift costs to automobile insurance ... hospital bills prior to payment. , ... Malvern, PA (Vocus) April 23, 2010 -- According to a new study from ...
... ... lipoplasty will be discussed by leading experts at the Annual Meeting of the American ... Convention Center April 23-27, 2010. “Point/Counterpoint – Laser Lipoplasty – Hype or Useful ... and Jeffrey M. Kenkel, MD. , ...
... at risk for facial deformities, poor grades, dentists say ... the mouth instead of the nose can lead to ... mouth breathers, most often children with allergies, have problems ... size, weight, sleep and even school performance, a recent ...
... INDIANAPOLIS Structural and functional congenital cardiovascular abnormalities present ... defects encountered in live births. Nearly half a million ... ranging in severity from relatively simple issues, such as ... severe malformations, including complete absence of one or more ...
... ... will be pleased with the final result, there is a small chance ... The realities of revision in rhinoplasty will be discussed by leading experts ... Aesthetic Plastic Surgery (ASAPS), being held at the Gaylord National Hotel and ...
Cached Medicine News:Health News:Hospital Cost Shifting Adds to Auto Injury Claim Costs 2Health News:Hospital Cost Shifting Adds to Auto Injury Claim Costs 3Health News:Hospital Cost Shifting Adds to Auto Injury Claim Costs 4Health News:Laser Lipoplasty: Cutting Through the Hype 2Health News:Laser Lipoplasty: Cutting Through the Hype 3Health News:Allergy-Linked Mouth Breathing Spells Trouble for Kids 2Health News:Allergy-Linked Mouth Breathing Spells Trouble for Kids 3Health News:New strategies to improve treatment and avert heart failure in children 2Health News:New strategies to improve treatment and avert heart failure in children 3Health News:Chasing Perfection in the Nose: Revision Rhinoplasty 2Health News:Chasing Perfection in the Nose: Revision Rhinoplasty 3
DS 7600 Central Station...
... MedSystem III DLE (Drug List Editor) Multi-Channel ... drug infusion technology. The instrument combines three ... clinical versatility in an unparalleled small size. ... MedSystem III Infusion System simplifies the delivery ...
... Freedom Chart Manager provides powerful workflow tools ... management, integrated transcription services, and customized flow ... that eliminates the need for paper charts. ... of a paperless office now and can ...
... ChartingPlus proves itself to over 2,000 ... Designed with the user in mind, ChartingPlus ... powerful and dynamic features to improve documentation ... practice. Our medical content is ...
Medicine Products: